NASDAQ:EQ Equillium (EQ) Stock Price, News & Analysis $0.82 +0.02 (+2.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.77▼$0.8250-Day Range$0.66▼$1.5552-Week Range$0.45▼$3.25Volume47,341 shsAverage Volume318,242 shsMarket Capitalization$28.83 millionP/E RatioN/ADividend YieldN/APrice Target$3.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Equillium alerts: Email Address Equillium MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside376.9% Upside$3.90 Price TargetShort InterestHealthy1.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$8,700 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.12) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.38 out of 5 starsMedical Sector381st out of 936 stocksPharmaceutical Preparations Industry181st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingEquillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEquillium has only been the subject of 1 research reports in the past 90 days.Read more about Equillium's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.20% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently decreased by 33.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EQ. Previous Next 3.9 News and Social Media Coverage News SentimentEquillium has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Equillium this week, compared to 1 article on an average week.Search Interest2 people have searched for EQ on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Equillium to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,700.00 in company stock.Percentage Held by Insiders30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.05% of the stock of Equillium is held by institutions.Read more about Equillium's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Equillium are expected to decrease in the coming year, from ($0.12) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Equillium's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Equillium Stock (NASDAQ:EQ)Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Read More EQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EQ Stock News HeadlinesJuly 20, 2024 | finance.yahoo.comEquillium Announces Second Quarter 2024 Estimated Cash and Investments BalanceJuly 16, 2024 | americanbankingnews.comEquillium, Inc. (NASDAQ:EQ) Short Interest UpdateJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 12, 2024 | businesswire.comEquillium to be included in the Russell Microcap® IndexJune 5, 2024 | businesswire.comEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | stocknews.com3 Biotech Stocks Under $20 Worth Watching in JuneMay 29, 2024 | businesswire.comEquillium to Present at the Jefferies Global Healthcare ConferenceMay 28, 2024 | finance.yahoo.comGraft versus Host Disease (GvHD) Pipeline Insights Report, 2024: Reveals 60+ Companies Engaged in Advancing 65+ Pipeline DrugsJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Equillium on Milestones and Financial ProspectsMay 14, 2024 | markets.businessinsider.comBuy Rating on Equillium as Promising Trials and Financial Stability Signal Upside PotentialMay 14, 2024 | businesswire.comEquillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseMay 9, 2024 | msn.comEQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | businesswire.comEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical HighlightsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Equillium on Strong itolizumab Data and Promising EQ101 Phase 2 ProspectsMay 2, 2024 | finance.yahoo.comWe're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn RateApril 3, 2024 | businesswire.comEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial UpsidesSee More Headlines Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EQ CUSIPN/A CIK1746466 Webequilliumbio.com Phone(858) 240-1200FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$3.90 High Stock Price Target$5.00 Low Stock Price Target$2.80 Potential Upside/Downside+400.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,340,000.00 Net Margins-32.01% Pretax Margin-30.64% Return on Equity-51.20% Return on Assets-23.31% Debt Debt-to-Equity RatioN/A Current Ratio1.91 Quick Ratio1.91 Sales & Book Value Annual Sales$36.08 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.22Miscellaneous Outstanding Shares35,260,000Free Float24,573,000Market Cap$27.50 million OptionableNot Optionable Beta1.82 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Daniel Mark Bradbury (Age 63)Executive Chairman Comp: $158kMr. Bruce D. Steel C.F.A. (Age 58)Co-Founder, President, CEO & Director Comp: $779.87kMs. Christine Zedelmayer M.B.A. (Age 54)P.M.P., Senior VP & COO Comp: $553.73kDr. Stephen Connelly Ph.D. (Age 42)Chief Scientific Officer & Director Comp: $571.32kMr. Jason A. Keyes (Age 53)Chief Financial Officer Penny TomSenior VP of Finance & Principal Accounting OfficerMr. Michael MooreVice President of Investor Relations & Corporate CommunicationsDr. Matthew Ritter Ph.D.Senior Vice President of Corporate DevelopmentMr. Joel M. Rothman (Age 55)Chief Development Officer Dr. Maple Fung M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRCybinNYSE:CYBNOptiNoseNASDAQ:OPTNRAPT TherapeuticsNASDAQ:RAPTWerewolf TherapeuticsNASDAQ:HOWLView All CompetitorsInsiders & InstitutionsJason A KeyesSold 10,000 sharesTotal: $8,700.00 ($0.87/share)Acadian Asset Management LLCBought 108,691 shares on 5/10/2024Ownership: 0.308%View All Insider TransactionsView All Institutional Transactions EQ Stock Analysis - Frequently Asked Questions How have EQ shares performed this year? Equillium's stock was trading at $0.7230 on January 1st, 2024. Since then, EQ stock has increased by 13.1% and is now trading at $0.8177. View the best growth stocks for 2024 here. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $10.69 million for the quarter, compared to analyst estimates of $9.15 million. Equillium had a negative net margin of 32.01% and a negative trailing twelve-month return on equity of 51.20%. What is Geoffrey A. Rotstein's approval rating as Equillium's CEO? 10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend. When did Equillium IPO? Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EQ) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EQ Stock Alerts